AI Takes Center Stage at Pharmaceutical Conference, Overshadowing US Tariff Concerns

AI Revolutionizes Pharmaceutical Industry

The pharmaceutical industry is witnessing a significant shift towards artificial intelligence (AI) adoption, as highlighted at a recent conference in India. Industry leaders and experts gathered to discuss the transformative potential of AI in drug development, clinical trials, and medical diagnostics 1

1

2

2

.

Accelerating Drug Development with AI

One of the most promising applications of AI in pharmaceuticals is its ability to expedite the drug development process. Chaitanya Royyuru, a partner at consulting firm EY, estimates that AI could potentially halve both the cost and time required for drug development, from discovery through commercial production 1

1

. This is a significant improvement over the traditional process, which typically takes more than a decade and costs around $1 billion.

AI in Clinical Trials and Safety Reporting

Contract manufacturers are leveraging AI to streamline various aspects of clinical trials. U.S.-based Parexel, for instance, is piloting an AI model that can generate drug safety reports 30-45 minutes faster than manual processes 1

1

2

2

. These AI-generated reports are subsequently verified by human experts, ensuring accuracy while significantly reducing processing time.

Enhancing Medical Diagnostics

Beyond drug discovery, AI is making substantial inroads in medical image analysis. Dr. Nageshwar Reddy, chairman of the Asian Institute of Gastroenterology, shared an example of AI's potential in radiology:

"Sometimes, when we look at an X-ray and we think it's normal, but AI says look, there's a small cancer you're missing. And when we actually look at it very carefully and follow the patient, there's a cancer coming there" 1

1

2

2

.

This demonstrates AI's ability to assist doctors in identifying subtle anomalies that might otherwise go unnoticed, potentially improving early detection rates for various conditions.

Industry-Wide AI Integration

The conference emphasized the importance of widespread AI adoption across the pharmaceutical sector. Ken Washington, chief technological officer at Medtronic, succinctly stated, "The bottom line is that AI has to be everybody's job" 1

1

2

2

. This underscores the growing consensus that AI integration is becoming essential for maintaining competitiveness in the industry.

US Tariff Concerns Loom

While AI dominated the conference discussions, the specter of potential U.S. tariffs on pharmaceutical imports cast a shadow over the proceedings. India, being among the top exporters of pharmaceuticals to the U.S., particularly for generic versions of popular drugs, could be significantly impacted by such tariffs 1

1

2

2

.

Cautious Approach to Tariff Threats

Despite the looming threat, many drugmakers are adopting a wait-and-watch approach. Nandini Piramal, chairperson at Piramal Pharma, expressed the industry's cautious stance:

"Right now, it's wait and watch. There is no clarity on what the tariffs are, if any, or if there is a transition period" 1

1

2

2

.

This uncertainty has led companies to hold off on making significant strategic decisions until more concrete information about the proposed tariffs becomes available.